NO970519L - Behandling av type II diabetes mellitus med amylinagonister - Google Patents

Behandling av type II diabetes mellitus med amylinagonister

Info

Publication number
NO970519L
NO970519L NO970519A NO970519A NO970519L NO 970519 L NO970519 L NO 970519L NO 970519 A NO970519 A NO 970519A NO 970519 A NO970519 A NO 970519A NO 970519 L NO970519 L NO 970519L
Authority
NO
Norway
Prior art keywords
diabetes mellitus
type
treatment
amylin agonists
amylin
Prior art date
Application number
NO970519A
Other languages
English (en)
Norwegian (no)
Other versions
NO970519D0 (no
Inventor
Orville G Kolterman
Robert G Thompson
John F Mullane
Original Assignee
Amylin Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amylin Pharmaceuticals Inc filed Critical Amylin Pharmaceuticals Inc
Publication of NO970519D0 publication Critical patent/NO970519D0/no
Publication of NO970519L publication Critical patent/NO970519L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO970519A 1995-06-07 1997-02-05 Behandling av type II diabetes mellitus med amylinagonister NO970519L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/483,188 US6143718A (en) 1995-06-07 1995-06-07 Treatment of Type II diabetes mellutis with amylin agonists
PCT/US1996/009875 WO1996040220A1 (en) 1995-06-07 1996-06-07 Treatment of type ii diabetes mellitus with amylin agonists

Publications (2)

Publication Number Publication Date
NO970519D0 NO970519D0 (no) 1997-02-05
NO970519L true NO970519L (no) 1997-04-07

Family

ID=23919034

Family Applications (1)

Application Number Title Priority Date Filing Date
NO970519A NO970519L (no) 1995-06-07 1997-02-05 Behandling av type II diabetes mellitus med amylinagonister

Country Status (19)

Country Link
US (2) US6143718A (enEXAMPLES)
EP (1) EP0772451B1 (enEXAMPLES)
JP (1) JP4009319B2 (enEXAMPLES)
AT (1) ATE228849T1 (enEXAMPLES)
AU (1) AU721489B2 (enEXAMPLES)
BG (1) BG101230A (enEXAMPLES)
CA (1) CA2196999C (enEXAMPLES)
CZ (1) CZ289043B6 (enEXAMPLES)
DE (1) DE69625157T2 (enEXAMPLES)
DK (1) DK0772451T3 (enEXAMPLES)
ES (1) ES2187659T3 (enEXAMPLES)
HU (1) HUP9700368A3 (enEXAMPLES)
IN (1) IN181672B (enEXAMPLES)
NO (1) NO970519L (enEXAMPLES)
PT (1) PT772451E (enEXAMPLES)
RU (1) RU2166958C2 (enEXAMPLES)
SK (1) SK18697A3 (enEXAMPLES)
WO (1) WO1996040220A1 (enEXAMPLES)
ZA (1) ZA964838B (enEXAMPLES)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU222249B1 (hu) * 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
ES2154299T3 (es) * 1993-09-07 2001-04-01 Amylin Pharmaceuticals Inc Metodos para la regulacion de la motilidad gastrointestinal.
US6143718A (en) * 1995-06-07 2000-11-07 Amylin Pharmaceuticals, Inc. Treatment of Type II diabetes mellutis with amylin agonists
US6410511B2 (en) 1997-01-08 2002-06-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US7312196B2 (en) 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US7101853B2 (en) * 1997-05-06 2006-09-05 Amylin Pharmaceuticals, Inc. Method for treating or preventing gastritis using amylin or amylin agonists
US7910548B2 (en) * 1997-06-06 2011-03-22 Amylin Pharmaceuticals, Inc. Methods for treating obesity
DK1044015T3 (da) * 1998-01-09 2008-12-08 Amylin Pharmaceuticals Inc Formuleringer med amylinagonistpeptider og insulin
US6087334A (en) * 1998-08-21 2000-07-11 Amylin Pharmaceuticals, Inc. Anti-diabetic peptides
AU2003235742B2 (en) * 2002-01-08 2008-08-07 Amylin Pharmaceuticals, Llc Use of Amylin agonists to modulate triglycerides
WO2004004665A2 (en) * 2002-07-09 2004-01-15 Bristol-Myers Squibb Company Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
BRPI0411165A (pt) * 2003-05-14 2006-07-11 Emisphere Tech Inc composição farmacêutica, forma de unidade de dosagem e métodos para preparar seu uso
US8501473B2 (en) * 2003-07-16 2013-08-06 Evotec International Gmbh Use of pleitrophin for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
NZ571824A (en) 2004-02-11 2010-04-30 Amylin Pharmaceuticals Inc Amylin family peptides and methods for making and using them
WO2005082401A1 (en) * 2004-02-20 2005-09-09 Rinat Neuroscience Corp. Methods of treating obesity or diabetes using nt-4/5
US7399744B2 (en) * 2004-03-04 2008-07-15 Amylin Pharmaceuticals, Inc. Methods for affecting body composition
AU2006223161B2 (en) * 2005-03-11 2011-05-12 Endo Pharmaceuticals Solutions Inc. Controlled release formulations of octreotide
US7759312B2 (en) * 2005-03-11 2010-07-20 Endo Pharmaceuticals Solutions Inc. Delivery of dry formulations of octreotide
JP2009528985A (ja) * 2006-02-02 2009-08-13 ライナット ニューロサイエンス コーポレイション ｔｒｋＢアゴニストを投与することにより望まれない体重減少または摂食障害を治療する方法
WO2007088479A1 (en) * 2006-02-02 2007-08-09 Rinat Neuroscience Corp. Methods for treating obesity by administering a trkb antagonist
AU2007337809A1 (en) * 2006-12-20 2008-07-03 Rinat Neuroscience Corporation TrkB agonists for treating autoimmune disorders
UA97707C2 (ru) * 2007-11-14 2012-03-12 Амилин Фармасьютикалз, Инк. Способы лечения ожирения и заболеваний, расстройств, связанных с ожирением
JP5622725B2 (ja) 2008-06-25 2014-11-12 エンド ファーマスーティカルズ ソリューションズ インコーポレイテッド．Ｅｎｄｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｓｏｌｕｔｉｏｎｓｉｎｃ． エキセナチド及び他のポリペプチド類の持続的送達
WO2009158415A1 (en) * 2008-06-25 2009-12-30 Endo Pharmaceuticals Solutions Inc. Octreotide implant having a release agent
NZ592283A (en) 2008-10-17 2012-09-28 Sanofi Aventis Deutschland Combination of an insulin and the GLP-1 agonist AVE0010
JP2009149684A (ja) * 2009-03-11 2009-07-09 Amylin Pharmaceut Inc アミリン作動薬ペプチド用製剤
RU2537181C2 (ru) * 2009-03-12 2014-12-27 Нордик Байосайенс А/С Лечение диабета и метаболического синдрома
US20110118180A1 (en) * 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Method of treatment of diabetes type 2 comprising add-on therapy to metformin
CN107308442B (zh) 2009-11-13 2022-10-18 赛诺菲-安万特德国有限公司 包含glp-1激动剂、胰岛素和甲硫氨酸的药物组合物
US20110118178A1 (en) * 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin
DK2498801T3 (en) 2009-11-13 2018-05-07 Sanofi Aventis Deutschland PHARMACEUTICAL COMPOSITION INCLUDING desPro36Exendin-4 (1-39) -Lys6-NH2 AND METHIONIN
BR112013004756B1 (pt) 2010-08-30 2020-04-28 Sanofi Aventis Deutschland uso de ave0010 para a fabricação de um medicamento para o tratamento da diabetes melito tipo 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
JP6367115B2 (ja) 2011-08-29 2018-08-01 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ２型糖尿病患者の血糖コントロールに使用する組合せ医薬
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
BR102013017626A2 (pt) * 2013-06-14 2015-02-10 Univ Rio De Janeiro Bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, uso de bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, composições farmacêuticas de baixa toxicidade, adjuvante para a prevenção ou tratamento das doenças, medicamento, método de tratamento ou prevenção de doenças.
TW201625671A (zh) * 2014-09-04 2016-07-16 諾佛 儂迪克股份有限公司 新穎澱粉素及降鈣素受體促效劑
US9950039B2 (en) 2014-12-12 2018-04-24 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8720115D0 (en) * 1987-08-26 1987-09-30 Cooper G J S Treatment of diabetes mellitus
US5367052A (en) * 1987-04-27 1994-11-22 Amylin Pharmaceuticals, Inc. Amylin peptides
US5266561A (en) * 1988-01-11 1993-11-30 Amylin Pharmaceuticals, Inc. Treatment of type 2 diabetes mellitus
US5175145A (en) * 1988-08-26 1992-12-29 Amylin Pharmaceuticals, Inc. Treatment of diabetes mellitus with amylin agonists
US5264372A (en) * 1991-03-15 1993-11-23 Amylin Pharmaceuticals, Inc. Receptor-based screening methods for amylin agonists and antagonists
US5234906A (en) * 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions
US5321008A (en) * 1991-01-10 1994-06-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions
HU222249B1 (hu) * 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
CZ288029B6 (cs) * 1991-11-19 2001-04-11 Amylin Pharmaceuticals, Inc. Agonizující analog amylinu, tento analog pro použití jako léčivo a farmaceutický prostředek obsahující tento analog
US5376638A (en) * 1992-09-01 1994-12-27 Amylin Pharmaceuticals, Inc. Methods for treating renin-related disorders with amylin antagonists
ES2154299T3 (es) * 1993-09-07 2001-04-01 Amylin Pharmaceuticals Inc Metodos para la regulacion de la motilidad gastrointestinal.
US6143718A (en) * 1995-06-07 2000-11-07 Amylin Pharmaceuticals, Inc. Treatment of Type II diabetes mellutis with amylin agonists
US6087334A (en) 1998-08-21 2000-07-11 Amylin Pharmaceuticals, Inc. Anti-diabetic peptides

Also Published As

Publication number Publication date
EP0772451A4 (en) 1998-09-30
ZA964838B (en) 1997-02-24
AU721489B2 (en) 2000-07-06
CA2196999C (en) 2012-09-04
HUP9700368A3 (en) 2001-03-28
HU9700368D0 (en) 1997-04-28
DE69625157D1 (de) 2003-01-16
WO1996040220A1 (en) 1996-12-19
ATE228849T1 (de) 2002-12-15
JPH10503785A (ja) 1998-04-07
DE69625157T2 (de) 2003-04-17
US6417164B1 (en) 2002-07-09
CA2196999A1 (en) 1996-12-19
SK18697A3 (en) 1998-02-04
EP0772451B1 (en) 2002-12-04
CZ33797A3 (en) 1997-07-16
US6143718A (en) 2000-11-07
RU2166958C2 (ru) 2001-05-20
DK0772451T3 (da) 2003-01-06
IN181672B (enEXAMPLES) 1998-08-29
HUP9700368A2 (hu) 1998-06-29
BG101230A (en) 1997-10-31
PT772451E (pt) 2003-04-30
CZ289043B6 (cs) 2001-10-17
ES2187659T3 (es) 2003-06-16
AU6268596A (en) 1996-12-30
JP4009319B2 (ja) 2007-11-14
NO970519D0 (no) 1997-02-05
EP0772451A1 (en) 1997-05-14

Similar Documents

Publication Publication Date Title
NO970519L (no) Behandling av type II diabetes mellitus med amylinagonister
EA199800316A1 (ru) СЕЛЕКТИВНЫЕ β-АДРЕНЕРГИЧЕСКИЕ АГОНИСТЫ
EA200200503A1 (ru) Способ лечения ревматоидного артрита
CA2071629A1 (en) Use of insulin sensitizing agents to treat hypertension
DK0867178T3 (da) Non-allosteriske GABA A agonister til behandling af søvnforstyrrelser
YU48666B (sh) Mometason furoat monohidrat i postupak za njegovo dobijanje
EE03202B1 (et) Intravaginaalne manustussüsteem ja selle valmistamismeetod
NO976063L (no) Fremgangsmåte for behandling av diabetes
UA29484C2 (uk) Спосіб лікування міокардиту, кардіоміопатії, ендокардиту і перикардиту
CY1105254T1 (el) Θepαπεια του διαβητη με θειαζολιδινδιονη, εκκριταγωγο ινσουλινης και διγουανιδιο
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
BR9810444A (pt) Tratamento de diabete com rosiglitazona e insulina
EA200100133A1 (ru) Оксазолидиноны для лечения инфекционных болезней глаз
EA199800864A1 (ru) Способ лечения при боли, вызванной мигренью
PT888330E (pt) Metodos de tratamento ou prevencao de cistite intersticial
EA200000140A1 (ru) Способ лечения диабета тиазолидиндионом, средством, усиливающим секрецию инсулина, и ингибитором альфа-глюкозидазы
BR9810186A (pt) Tratamento de diabete com tiazolidinadiona e inibidor de alfa-glicosidade
BR9810142A (pt) Tratamento de diabete com tiazolidinadiona e sulfonil-uréia
TW330933B (en) Furanoeremophilane and eremophilanolide sesquiterpenes for treatment of diabetes
PT869785E (pt) 4-hidroxicumarina-3-carboxamidas para o tratamento de diabetes mellitus nao insulinodependente
SE8800461D0 (sv) Farmaceutisk komposition
NO993069L (no) Ny anvendelse av dipeptider
EA199800822A1 (ru) Способ лечения избыточной агрессии
TR200000957T2 (tr) Hiperglisemi tedavisinde tiazolidinedion kullanımı
NO985325L (no) Anvendelse av substituert azaspiran ved behandling av astma